EBITDA: Income before interest, taxes, depreciation and amortization.
Compass Therapeutics, Inc. (CMPX) had EBITDA of $-17.58M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-16.63M |
|
-- |
|
-- |
|
$17.97M |
|
$-17.97M |
|
$1.33M |
|
$-16.63M |
|
$-16.63M |
|
$-16.63M |
|
$-16.63M |
|
$-16.63M |
|
$-16.63M |
|
$-17.97M |
|
|
EBITDA |
$-17.58M |
138.24M |
|
138.24M |
|
$-0.12 |
|
$-0.12 |
|
| Balance Sheet Financials | |
$124.14M |
|
$0.23M |
|
$7.31M |
|
$131.45M |
|
$14.90M |
|
-- |
|
$6.27M |
|
$21.17M |
|
$110.28M |
|
$110.28M |
|
$110.28M |
|
138.28M |
|
| Cash Flow Statement Financials | |
$-13.21M |
|
$11.59M |
|
$-0.81M |
|
$44.05M |
|
$41.62M |
|
$-2.44M |
|
$2.51M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.33 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-13.23M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-15.08% |
|
-15.08% |
|
-12.65% |
|
-15.08% |
|
$0.80 |
|
$-0.10 |
|
$-0.10 |
|